valproic acid has been researched along with Chronic Insomnia in 9 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To correlate lamotrigine (LTG) serum concentrations (levels) with tolerability in patients with epilepsy." | 8.82 | Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy. ( Adams, DJ; Bazil, CW; Buchsbaum, R; Du, Y; Hager, M; Hirsch, LJ; Morrell, MJ; Resor, SR; Spencer, HT; Straka, T; Weintraub, D, 2004) |
| "To correlate lamotrigine (LTG) serum concentrations (levels) with tolerability in patients with epilepsy." | 4.82 | Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy. ( Adams, DJ; Bazil, CW; Buchsbaum, R; Du, Y; Hager, M; Hirsch, LJ; Morrell, MJ; Resor, SR; Spencer, HT; Straka, T; Weintraub, D, 2004) |
| "A 47-year-old white man with a history of bipolar disorder was being maintained on citalopram 40 mg once daily and zolpidem 5 mg at bedtime." | 3.72 | Somnambulism due to probable interaction of valproic acid and zolpidem. ( Bhatia, SC; Petty, F; Ramaswamy, S; Sattar, SP, 2003) |
| " During the randomization phase, the most common adverse events occurring in > or =5% in the quetiapine group were somnolence, nasopharyngitis, and headache." | 2.73 | Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). ( Brecher, M; Eggens, I; Paulsson, B; Persson, I; Suppes, T; Vieta, E, 2008) |
| " The adverse effect (AE) profile of this combination needs clarification." | 2.69 | Adding lamotrigine to valproate: incidence of rash and other adverse effects. Postmarketing Antiepileptic Drug Survey (PADS) Group. ( Faught, E; French, J; Harden, C; Jacobson, M; Montouris, G; Morris, G; Rosenfeld, W, 1999) |
| "Clobazam is a 1,5-benzodiazepine effective in antiepileptic therapy of children and adults." | 1.30 | Interactions of clobazam with conventional antiepileptics in children. ( Cortez, M; Daneman, R; Hwang, P; Koren, G; Menzano, E; Sherwin, AL; Theis, JG, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Prieto, DI | 1 |
| Zehgeer, AA | 1 |
| Connor, DF | 1 |
| Vieta, E | 1 |
| Suppes, T | 1 |
| Eggens, I | 1 |
| Persson, I | 1 |
| Paulsson, B | 1 |
| Brecher, M | 1 |
| Levin, IaI | 1 |
| Tarasov, BA | 1 |
| Sattar, SP | 1 |
| Ramaswamy, S | 1 |
| Bhatia, SC | 1 |
| Petty, F | 1 |
| Hirsch, LJ | 1 |
| Weintraub, D | 1 |
| Du, Y | 1 |
| Buchsbaum, R | 1 |
| Spencer, HT | 1 |
| Hager, M | 1 |
| Straka, T | 1 |
| Bazil, CW | 1 |
| Adams, DJ | 1 |
| Resor, SR | 1 |
| Morrell, MJ | 1 |
| Kratochvil, CJ | 1 |
| Varley, C | 1 |
| Cummins, TK | 1 |
| Martin, A | 1 |
| Siniscalchi, A | 1 |
| Gallelli, L | 1 |
| De Fazio, S | 1 |
| De Sarro, G | 1 |
| Theis, JG | 1 |
| Koren, G | 1 |
| Daneman, R | 1 |
| Sherwin, AL | 1 |
| Menzano, E | 1 |
| Cortez, M | 1 |
| Hwang, P | 1 |
| Faught, E | 1 |
| Morris, G | 1 |
| Jacobson, M | 1 |
| French, J | 1 |
| Harden, C | 1 |
| Montouris, G | 1 |
| Rosenfeld, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study of Prophylactic Management of Lamotrigine for Bipolar Disorder in Pregnant Women[NCT03774641] | 20 participants (Anticipated) | Observational | 2018-12-03 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for valproic acid and Chronic Insomnia
| Article | Year |
|---|---|
Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy.
Topics: Anticonvulsants; Dose-Response Relationship, Drug; Drug Eruptions; Drug Interactions; Drug Therapy, | 2004 |
3 trials available for valproic acid and Chronic Insomnia
| Article | Year |
|---|---|
Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126).
Topics: Antipsychotic Agents; Bipolar Disorder; Demography; Dibenzothiazepines; Disorders of Excessive Somno | 2008 |
[Influence of ivadal and depakene chrono on sleep structure in patients with epilepsy].
Topics: Adult; Delayed-Action Preparations; Drug Administration Schedule; Electroencephalography; Electroocu | 2003 |
Adding lamotrigine to valproate: incidence of rash and other adverse effects. Postmarketing Antiepileptic Drug Survey (PADS) Group.
Topics: Adolescent; Adult; Child; Dizziness; Drug Eruptions; Drug Hypersensitivity; Drug Therapy, Combinatio | 1999 |
5 other studies available for valproic acid and Chronic Insomnia
| Article | Year |
|---|---|
Use of Suvorexant for Sleep Regulation in an Adolescent with Early-Onset Bipolar Disorder.
Topics: Adolescent; Anticonvulsants; Antipsychotic Agents; Azepines; Bipolar Disorder; Humans; Lurasidone Hy | 2019 |
Somnambulism due to probable interaction of valproic acid and zolpidem.
Topics: Bipolar Disorder; Citalopram; Depression; Drug Interactions; Drug Therapy, Combination; Humans; Male | 2003 |
Less is more: inpatient management of a child with complex pharmacotherapy.
Topics: Aggression; Amphetamines; Attention Deficit Disorder with Hyperactivity; Child; Clonidine; Depressio | 2006 |
Psychic disturbances associated with sodium valproate plus levetiracetam.
Topics: Anticonvulsants; Anxiety; Drug Therapy, Combination; Epilepsies, Partial; Female; Humans; Levetirace | 2007 |
Interactions of clobazam with conventional antiepileptics in children.
Topics: Adolescent; Age Factors; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Benzodiazepinones; C | 1997 |